KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Accumulated Expenses (2016 - 2025)

Emergent BioSolutions' Accumulated Expenses history spans 16 years, with the latest figure at $41.8 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 25.49% year-over-year to $41.8 million; the TTM value through Dec 2025 reached $41.8 million, down 25.49%, while the annual FY2025 figure was $41.8 million, 25.49% down from the prior year.
  • Accumulated Expenses reached $41.8 million in Q4 2025 per EBS's latest filing, up from $13.9 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $73.4 million in Q3 2021 to a low of $13.6 million in Q2 2025.
  • Average Accumulated Expenses over 5 years is $40.1 million, with a median of $38.0 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: surged 272.35% in 2024, then plummeted 79.61% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $51.7 million in 2021, then tumbled by 32.5% to $34.9 million in 2022, then tumbled by 46.7% to $18.6 million in 2023, then skyrocketed by 201.61% to $56.1 million in 2024, then fell by 25.49% to $41.8 million in 2025.
  • Per Business Quant, the three most recent readings for EBS's Accumulated Expenses are $41.8 million (Q4 2025), $13.9 million (Q3 2025), and $13.6 million (Q2 2025).